Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
Carlyle and Abingworth’s $170 Million Non-dilutive Financing of Opthea
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...